Skip to main content
Signal8
Launch Terminal

COMPASS Pathways plc (CMPS)

COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

COMPASS Pathways plc logo

COMPASS Pathways plc

NASDAQ:CMPSHealthcare
-5.09%$11.57
AH$11.63+0.52%vs close
Mkt Cap$1.6B
Float127.2M
O/S138.48M
Vol
$ Vol
RVOL
Inst Own65.6%
SI13.9%
Earnings
Dilution
COMPASS Pathways plc logoNASDAQ:CMPS$11.57-5.09%
FormDescription
13G
Beneficial Ownership Report
144
Notice of Proposed Sale of Securities
144
Notice of Proposed Sale of Securities
4
Statement of Changes in Beneficial Ownership
S-3ASR
SEC Filing
6
8-K
2.02,9.01
5
10-Q
Quarterly Report
7
8-K
7.01,8.01,9.01
3
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
3
Initial Statement of Beneficial Ownership
8-K
5.07
13G/A
Beneficial Ownership Report (Amended)
8-K
2.02,9.01
1
10-Q
Quarterly Report
ARS
SEC Filing
DEF 14A
Definitive Proxy Statement
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership

1-25 of 342

…